Qsymia Capsules In Pakistan | Wellora.pk

Dosing Forms & Strengths

Phentermine (immediate-release)/topiramate (extended-release)

capsule: Schedule IV

3.75mg/23mg

7.5mg/46mg

11.25mg/69mg

15mg/92mg

Weight Management

Indicated as an adjunct to a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults who are obese or overweight in the presence of ≥1 weight-related comorbid condition

Initial: 3.75 mg/23 mg PO qDay for 14 days, THEN

Day 15: Increase to 7.5 mg/46 mg PO qDay for 12 weeks, then evaluate weight loss

After 12 weeks at 7.5 mg/46 mg: Evaluate weight loss; if adult has not lost at least 3% of baseline body weight, increase to 11.25 mg/69 mg qDay for 14 days; followed by an increase to 15 mg/92 mg qDay

After 12 weeks at 15 mg/92 mg: Evaluate weight loss for adults; if adult has not lost at least 5% of baseline body weight, discontinue phentermine/topiramate, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment

Note: 3.75 mg/23 mg and 11.25 mg/69 mg dosage strengths are for titration purposes only

Dosage Modifications

Renal impairment

Mild (≥50 mL/min): No dose adjustment required

Moderate (30-49 mL/min) and severe (<30 mL/min): Not to exceed 7.5 mg/46 mg qDay

Hepatic impairment

Mild (Child-Pugh 5-6): No dose adjustment required

Moderate (Child-Pugh 7-9): Not to exceed 7.5 mg/46 mg qDay

Severe (Child-Pugh 10-15): Avoid use